• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 1, 2011

View Archived Issues

MAP, Allergan Collaborate on $157M Levadex Marketing Deal

MAP Pharmaceuticals Inc. and Allergan Inc. will collaborate on marketing MAP's Levadex, a self-administered, orally inhaled therapy for acute migraine in adults. MAP, of Mountain View, Calif., will get $60 million up-front and as much as $97 million if it meets milestones. Read More

Antisoma Shares Tank 64% as AML Drug Fails in Phase III

LONDON – Antisoma plc has taken a double hit with the failure of its only two clinical programs, as the lead product AS1413 failed in a pivotal Phase III trial in secondary acute myeloid leukemia (AML) and a Phase IIb trial of AS1411 in AML was halted after an interim analysis. Read More

Taligen Buy to 'Complement' Alexion Pharma's Portfolio

Alexion Pharmaceuticals Inc. acquired Taligen Therapeutics Inc. for $111 million up front with additional contingent payments based on clinical and regulatory milestones. Alexion ended 2010 with $297 million in the bank, so the Taligen acquisition was an affordable move allowing it to neutralize a future competitor and diversify its pipeline. Read More

NPS' Orphan Focus Pays Off; Gattex Hits Endpoints in SBS

Shares of NPS Pharmaceuticals Inc. jumped 31.5 percent on positive Phase III data for GLP-2 analogue Gattex (teduglutide) in short bowel syndrome (SBS), and the Bedminster, N.J.-based firm expects to submit a new drug application in the second half of this year. Read More

Depomed's Gralise Gets PHN Nod; Now Who Will Market?

Depomed Inc. scored a major win with the FDA's approval late Friday of its once-daily tablet formulation of gabapentin, branded Gralise, in postherpetic neuralgia, sending the company's shares soaring more than 34.3 percent Monday. Read More

Stock Movers

Read More

Clinic Roundup

Sinovac Biotech Ltd., of Beijing, submitted applications to the Chinese SFDA for clinical trials of its pneumococcal polysaccharide vaccines. Preclinical studies showed favorable safety and efficacy profiles in animals. Read More

Financings Roundup

Savient Pharmaceuticals Inc., of East Brunswick, N.J., said it will offer $125 million aggregate principal amount of convertible senior notes due 2018. The firm also plans to grant underwriters J.P. Morgan Securities LLC and Lazard Capital Markets LLC an option to purchase up to an additional $18.75 million aggregate principal amount of notes to cover overallotments. Read More

Other News To Note

Pfizer Inc., of New York, completed its tender offer for Bristol, Tenn.-based King Pharmaceuticals Inc. The firms agreed to an acquisition deal in October that valued King at $14.25 per share, or about $3.6 billion. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 24, 2025.
  • Illustration of group of people with chromosomes floating above

    A fresh look at 1000 Genomes is more detailed, and more panoramic

    BioWorld
    The human genome has yielded another round of secrets with the publication of two back-to-back papers in Nature on July 23, 2025. Both studies re-sequenced...
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • Stock chart, upward arrow

    Abivax’s obefazimod wows investors; stock climbs 500%+

    BioWorld
    Abivax SA is positioning to change the treatment landscape in ulcerative colitis after delivering positive results and a favorable safety profile in two phase III...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe